Background
The development of an in vitro cultivation system for human noroviruses allows the measurement of neutralizing antibody levels.
Conclusions
HBGA-blocking antibodies are a surrogate for neutralization in human noroviruses. Clinical trials registration: NCT02475278.
Methods
Serum neutralizing antibody levels were determined using a GII.4/Sydney/2012-like virus in human intestinal enteroids in samples collected before and 4 weeks after administration of an investigational norovirus vaccine and were compared with those measured in histo-blood group antigen (HBGA)-blocking assays.
Results
Neutralizing antibody seroresponses were observed in 71% of 24 vaccinated adults, and antibody levels were highly correlated (r = 0.82, P < .001) with those measured by HBGA blocking. Conclusions: HBGA-blocking antibodies are a surrogate for neutralization in human noroviruses. Clinical trials registration: NCT02475278.